Robinson Chandler 4
4 · Monopar Therapeutics · Filed Apr 2, 2025
Insider Transaction Report
Form 4
Robinson Chandler
DirectorChief Executive Officer
Transactions
- Tax Payment
Common Stock
2025-03-31$36.41/sh−1,204$43,838→ 65,993 total - Exercise/Conversion
Restricted Stock Units
2025-03-31−4,106→ 94,669 total→ Common Stock (4,106 underlying) - Exercise/Conversion
Common Stock
2025-03-31+4,106→ 67,197 total
Holdings
- 855,589(indirect: See Footnote)
Common Stock
Footnotes (5)
- [F1]Represents shares acquired on vesting and settlement of restricted stock units.
- [F2]Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.
- [F3]As a manager of Tactic Pharma LLC, Dr. Robinson may be deemed to share voting and dispositive power over these 855,589 shares. Dr. Robinson disclaims beneficial ownership of the 855,589 shares held by Tactic Pharma LLC, except to the extent of his pecuniary interest therein.
- [F4]On February 2, 2022, the reporting person was granted 31,905 restricted stock units, vesting 6/48ths (3,988 shares) on June 30, 2022, and 3/48ths (1,994 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
- [F5]On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.